108.35
前日終値:
$109.09
開ける:
$108.59
24時間の取引高:
82,471
Relative Volume:
0.01
時価総額:
$134.67B
収益:
$28.73B
当期純損益:
$5.97B
株価収益率:
22.81
EPS:
4.75
ネットキャッシュフロー:
$9.84B
1週間 パフォーマンス:
+1.65%
1か月 パフォーマンス:
+4.12%
6か月 パフォーマンス:
+17.20%
1年 パフォーマンス:
+70.87%
Gilead Sciences Inc Stock (GILD) Company Profile
GILD を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
GILD
Gilead Sciences Inc
|
108.26 | 134.00B | 28.73B | 5.97B | 9.84B | 4.75 |
![]()
LLY
Lilly Eli Co
|
721.00 | 650.81B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
152.86 | 368.56B | 89.33B | 21.81B | 18.57B | 8.99 |
![]()
ABBV
Abbvie Inc
|
183.79 | 321.13B | 57.37B | 4.20B | 15.39B | 2.35 |
![]()
NVS
Novartis Ag Adr
|
111.57 | 222.75B | 53.22B | 12.86B | 14.85B | 6.39 |
![]()
NVO
Novo Nordisk Adr
|
68.75 | 303.04B | 43.59B | 15.04B | 10.74B | 3.3766 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2024-12-10 | 再開されました | BofA Securities | Buy |
2024-11-15 | 開始されました | Wolfe Research | Outperform |
2024-11-14 | 開始されました | Citigroup | Buy |
2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
2024-10-17 | 開始されました | Bernstein | Outperform |
2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
2024-05-01 | 繰り返されました | Maxim Group | Buy |
2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
2024-02-22 | ダウングレード | Truist | Buy → Hold |
2023-11-09 | 開始されました | Deutsche Bank | Hold |
2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
2023-09-06 | 開始されました | HSBC Securities | Reduce |
2023-07-24 | 繰り返されました | Barclays | Equal Weight |
2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
2023-04-28 | 再開されました | Piper Sandler | Overweight |
2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2022-12-13 | 再開されました | BofA Securities | Neutral |
2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
2022-10-28 | 繰り返されました | Cowen | Outperform |
2022-10-28 | 繰り返されました | JP Morgan | Overweight |
2022-10-28 | 繰り返されました | Jefferies | Buy |
2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
2022-10-28 | アップグレード | Truist | Hold → Buy |
2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
2022-02-02 | 繰り返されました | BofA Securities | Neutral |
2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
2022-02-02 | 繰り返されました | Truist | Hold |
2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
2022-01-28 | アップグレード | Argus | Hold → Buy |
2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
2021-12-06 | 開始されました | Goldman | Neutral |
2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
2021-11-19 | 再開されました | Piper Sandler | Neutral |
2021-10-20 | 再開されました | Cowen | Outperform |
2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
2021-03-30 | アップグレード | Redburn | Neutral → Buy |
2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
2020-10-28 | 開始されました | UBS | Neutral |
2020-09-30 | 再開されました | Jefferies | Buy |
2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
2020-07-31 | 繰り返されました | SunTrust | Hold |
2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2020-05-26 | アップグレード | SunTrust | Sell → Hold |
2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
2020-04-27 | ダウングレード | UBS | Buy → Neutral |
2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Gilead Sciences and Kite Pharma To Announce Transformative - CSRwire
Gilead Sciences’ SWOT analysis: HIV giant faces oncology growth, patent cliff - Investing.com Nigeria
ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs - insights.citeline.com
Gilead Ready To Go After Hepatitis D Again - insights.citeline.com
Gilead Sciences' Best Days May Be AheadHere's Why (NASDAQ:GILD) - Seeking Alpha
GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer - Yahoo Finance
Gilead’s Phase III trial for breast cancer therapy meets primary goal - Clinical Trials Arena
Gilead Sciences, Inc. (GILD)’s Breast Cancer Study Success Drives Investor Optimism Amid Broader Market Slump - MSN
Gilead says Trodelvy ASCENT-03 study meets primary endpoint - The Pharma Letter
Gilead announces ASCENT-03 study meets primary endpoint - Yahoo Finance
Gilead Sciences (NasdaqGS:GILD) Announces Promising Phase 3 Results For Trodelvy In Breast Cancer - simplywall.st
Gilead (GILD) to Acquire HOOK for $10 million - Insider Monkey
Gilead Sciences (GILD) Achieves Key Trial Milestone with Trodelv - GuruFocus
After Keytruda combo win, Gilead's Trodelvy meets the mark in solo breast cancer trial - Fierce Pharma
Gilead (GILD) Announces Promising Results from Trodelvy Study | - GuruFocus
Gilead Sciences Says Trodelvy Met Primary Endpoint in Phase 3 Breast Cancer Trial - marketscreener.com
Gilead posts trial win for Trodelvy in breast cancer (GILD) - Seeking Alpha
Gilead (GILD) Announces Promising Results from Trodelvy Study | GILD Stock News - GuruFocus
ASCENT-03Trodelvy Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors - marketscreener.com
Gilead Sciences (GILD) announces positive data from Phase 3 Trodelvy study - StreetInsider
ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors - Business Wire
Gilead records another pivotal study success for Trodelvy in first-line TNBC - FirstWord Pharma
Sector Update: Health Care Stocks Softer Late Afternoon - marketscreener.com
Sector Update: Health Care Stocks Retreat Thursday Afternoon - marketscreener.com
HOOKIPA to Sell HBV, HIV Program Assets to Gilead; Shares Rise - marketscreener.com
Gilead (GILD) Experiences Significant Increase in Bearish Options Activity | GILD Stock News - GuruFocus
Gilead Sciences to Acquire HOOKIPA Pharma Assets for $10M - GuruFocus
Hookipa stock gains as Gilead eyes assets (HOOK:NASDAQ) - Seeking Alpha
Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs - Fierce Biotech
Hookipa Pharma Sells Assets to Gilead Sciences - TipRanks
What Analysts Are Saying About Gilead Sciences Stock - Benzinga
Tomas Cihlar, Gilead Sciences, Named to TIME’s List of 100 Most Influential People in the World for HIV Research - CSRwire
Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance
Gilead Sciences (GILD) Receives Hold Rating from Needham | GILD Stock News - GuruFocus
Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now? - Zacks Investment Research
Tomas Cihlar, Gilead Sciences, Named to TIME’s List of 10 - 3BL Media
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Unusual Options Alert: The Smart Money Is Piling Into Gilead Sciences (GILD) - Barchart.com
Gilead Sciences: Buy Rating Affirmed Amid Promising Lenacapavir Approval and Market Expansion - TipRanks
Gilead Sciences discovers new PRMT5 inhibitors - BioWorld MedTech
Gilead Sciences, Inc. (GILD) and Kite to Present Breakthrough Cancer Therapy Data at 2025 ASCO and EHA - Yahoo Finance
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus
Gilead Sciences (GILD) is Flashing a Quant Signal That Wall Street is Ignoring - Money Morning
Gilead Sciences: Bringing PBC Into Focus Through Art of Patient Stories - CSRwire
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences Inc (GILD) - GuruFocus
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and E - BioSpace
Does Gilead's drug lenacapavir have the power to end the AIDS epidemic?San Francisco Business Times - The Business Journals
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Th - GuruFocus
Gilead And Kite Announce Presentation Of Transformative Data In 1L Metastatic Triple-Negative Breast Cancer, Updated Results In Multiple Myeloma And Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer At 2025 ASCO And - marketscreener.com
Does Gilead's latest PreP drug lenacapavir have the power to end the AIDS epidemic?San Francisco Business Times - The Business Journals
Upcoming Meeting for GILD in Foster City | GILD Stock News - GuruFocus
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
Gilead Sciences Inc (GILD) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Mercier Johanna | Chief Commercial Officer |
May 22 '25 |
Sale |
107.52 |
28,000 |
3,010,564 |
121,152 |
大文字化:
|
ボリューム (24 時間):